These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 2290412)
1. Attenuation of the early anterior negativity of median nerve somatosensory evoked potential in the MPTP-treated monkey. Onofrj M; Ghilardi MF; Basciani M; Martinez-Tica J; Glover A Neurophysiol Clin; 1990 Oct; 20(4):283-93. PubMed ID: 2290412 [TBL] [Abstract][Full Text] [Related]
2. Effects of drug manipulations on anterior components of somatosensory evoked potentials in a parkinsonian animal model. Onofrj M; Ferracci F; Fulgente T; Malatesta G; Ghilardi MF Drugs Exp Clin Res; 1994; 20(1):29-36. PubMed ID: 7924892 [TBL] [Abstract][Full Text] [Related]
3. Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Ghilardi MF; Chung E; Bodis-Wollner I; Dvorzniak M; Glover A; Onofrj M Life Sci; 1988; 43(3):255-62. PubMed ID: 3260986 [TBL] [Abstract][Full Text] [Related]
4. Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson's disease and in parkinsonism. Rossini PM; Bassetti MA; Pasqualetti P Electroencephalogr Clin Neurophysiol; 1995 May; 96(3):236-47. PubMed ID: 7750449 [TBL] [Abstract][Full Text] [Related]
5. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Ghilardi MF; Bodis-Wollner I; Onofrj MC; Marx MS; Glover AA Brain; 1988 Feb; 111 ( Pt 1)():131-49. PubMed ID: 3259150 [TBL] [Abstract][Full Text] [Related]
6. Alterations in event-related potentials (ERPs) of MPTP-treated monkeys. Glover A; Ghilardi MF; Bodis-Wollner I; Onofrj M Electroencephalogr Clin Neurophysiol; 1988; 71(6):461-8. PubMed ID: 2460327 [TBL] [Abstract][Full Text] [Related]
7. The effects of stimulus rates upon median, ulnar and radial nerve somatosensory evoked potentials. Fujii M; Yamada T; Aihara M; Kokubun Y; Noguchi Y; Matsubara M; Yeh MH Electroencephalogr Clin Neurophysiol; 1994 Nov; 92(6):518-26. PubMed ID: 7527770 [TBL] [Abstract][Full Text] [Related]
8. Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients. de Mari M; Margari L; Lamberti P; Iliceto G; Ferrari E J Neural Transm Suppl; 1995; 45():171-6. PubMed ID: 8748623 [TBL] [Abstract][Full Text] [Related]
9. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824 [TBL] [Abstract][Full Text] [Related]
10. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Taylor JR; Elsworth JD; Roth RH; Sladek JR; Redmond DE Neuroscience; 1997 Dec; 81(3):745-55. PubMed ID: 9316026 [TBL] [Abstract][Full Text] [Related]
12. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. Goldberg JA; Boraud T; Maraton S; Haber SN; Vaadia E; Bergman H J Neurosci; 2002 Jun; 22(11):4639-53. PubMed ID: 12040070 [TBL] [Abstract][Full Text] [Related]
13. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? German DC; Dubach M; Askari S; Speciale SG; Bowden DM Neuroscience; 1988 Jan; 24(1):161-74. PubMed ID: 3259295 [TBL] [Abstract][Full Text] [Related]
14. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Marzatico F; Café C; Taborelli M; Benzi G Neurochem Res; 1993 Oct; 18(10):1101-6. PubMed ID: 8255359 [TBL] [Abstract][Full Text] [Related]
15. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860 [TBL] [Abstract][Full Text] [Related]
16. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)]. Degryse AD; Colpaert FC Brain Res Bull; 1986 May; 16(5):561-71. PubMed ID: 3488798 [TBL] [Abstract][Full Text] [Related]
17. Are frontal and parietal somatosensory evoked potentials functionally dissociated by changing stimulus rate? Huttunen J Int J Neurosci; 1994 Oct; 78(3-4):207-13. PubMed ID: 7883457 [TBL] [Abstract][Full Text] [Related]
18. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249 [TBL] [Abstract][Full Text] [Related]
19. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863 [TBL] [Abstract][Full Text] [Related]
20. A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys. Wolters EC; Kebabian JC; Guttman M; Mak E; Pate BD; Calne DB Neurosci Lett; 1988 Dec; 95(1-3):257-61. PubMed ID: 3265771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]